Filing Details

Accession Number:
0001104659-24-106060
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-10-03 21:53:54
Reporting Period:
2024-09-17
Accepted Time:
2024-10-03 21:53:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1720893 Bioxcel Therapeutics Inc. BTAI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1672718 Vincent O'neill C/O Bioxcel Therapeutics, Inc.
555 Long Wharf Drive, 12Th Floor
New Haven CT 06511
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-09-17 21,250 $0.00 25,157 No 4 A Direct
Common Stock Disposition 2024-10-03 5,556 $0.55 19,601 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through October 1, 2024 (the "PSUs"). On September 17, 2024, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 21,250 PSUs had been satisfied and 21,250 shares of common stock became issuable to the Reporting Person on October 1, 2024.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.
  3. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $0.5500 to $0.5501. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.